Immunohistochemistry contribution to the diagnosis of prostate cancer

INTRODUCTION: Efforts for the identification of prostate cancer in the initial clinical and pathological stages led to an increase in the number of biopsies, sometimes making the histological diagnosis of adenocarcinoma difficult. This is due to the presence of minimal carcinoma or atypical glands suspicious for carcinoma, also known as atypical small acinar proliferation (ASAP). In these cases, the use of immunohistochemistry (IHC) has become a common practice in laboratories of pathology. OBJECTIVES: The aims of this study were to assess the incidence of diagnoses of ASAP and minimal adenocarcinoma in two laboratories of pathology and to evaluate the contribution of IHC and repeat biopsy to the diagnosis of prostate cancer. METHODS: We reviewed 641 sets of modified sextant needle biopsies of the prostate performed in two laboratories of pathology between January 2005 and December 2010. IHC using 34βE12 and p63 antibodies was performed on 35 of 73 (11.38%) cases diagnosed as ASAP and on 7 (1.1%) cases diagnosed as minimal adenocarcinoma. RESULTS: The incidence of ASAP diagnosis was 11.38% (n = 73). IHC was performed in 35 of the 73 ASAP cases and provided conclusive results in 31 cases (88.57%), resulting in a final diagnosis of adenocarcinoma in 19 patients (54.28%), benign lesions in 12 patients (34 28%); only 4 (11.42%) were inconclusive. CONCLUSION: The results suggest that IHC should be routinely used in evaluation of borderline biopsies and in ASAP cases. IHC strongly contributes to the diagnosis of prostate cancer.

Saved in:
Bibliographic Details
Main Authors: Engelman,Míriam de Fátima Brasil, Mundim,Fiorita Gonzales Lopes, Grande,Rogério Mendes, Carvalho,Lucas Ribeiro Borges de, Ridolfi,Felipe Moreira
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Patologia Clínica 2012
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442012000400008
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S1676-24442012000400008
record_format ojs
spelling oai:scielo:S1676-244420120004000082012-09-24Immunohistochemistry contribution to the diagnosis of prostate cancerEngelman,Míriam de Fátima BrasilMundim,Fiorita Gonzales LopesGrande,Rogério MendesCarvalho,Lucas Ribeiro Borges deRidolfi,Felipe Moreira Prostate Immunohistochemistry Needle biopsy Adenocarcinoma INTRODUCTION: Efforts for the identification of prostate cancer in the initial clinical and pathological stages led to an increase in the number of biopsies, sometimes making the histological diagnosis of adenocarcinoma difficult. This is due to the presence of minimal carcinoma or atypical glands suspicious for carcinoma, also known as atypical small acinar proliferation (ASAP). In these cases, the use of immunohistochemistry (IHC) has become a common practice in laboratories of pathology. OBJECTIVES: The aims of this study were to assess the incidence of diagnoses of ASAP and minimal adenocarcinoma in two laboratories of pathology and to evaluate the contribution of IHC and repeat biopsy to the diagnosis of prostate cancer. METHODS: We reviewed 641 sets of modified sextant needle biopsies of the prostate performed in two laboratories of pathology between January 2005 and December 2010. IHC using 34βE12 and p63 antibodies was performed on 35 of 73 (11.38%) cases diagnosed as ASAP and on 7 (1.1%) cases diagnosed as minimal adenocarcinoma. RESULTS: The incidence of ASAP diagnosis was 11.38% (n = 73). IHC was performed in 35 of the 73 ASAP cases and provided conclusive results in 31 cases (88.57%), resulting in a final diagnosis of adenocarcinoma in 19 patients (54.28%), benign lesions in 12 patients (34 28%); only 4 (11.42%) were inconclusive. CONCLUSION: The results suggest that IHC should be routinely used in evaluation of borderline biopsies and in ASAP cases. IHC strongly contributes to the diagnosis of prostate cancer.info:eu-repo/semantics/openAccessSociedade Brasileira de Patologia Clínica Jornal Brasileiro de Patologia e Medicina Laboratorial v.48 n.4 20122012-08-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442012000400008en10.1590/S1676-24442012000400008
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Engelman,Míriam de Fátima Brasil
Mundim,Fiorita Gonzales Lopes
Grande,Rogério Mendes
Carvalho,Lucas Ribeiro Borges de
Ridolfi,Felipe Moreira
spellingShingle Engelman,Míriam de Fátima Brasil
Mundim,Fiorita Gonzales Lopes
Grande,Rogério Mendes
Carvalho,Lucas Ribeiro Borges de
Ridolfi,Felipe Moreira
Immunohistochemistry contribution to the diagnosis of prostate cancer
author_facet Engelman,Míriam de Fátima Brasil
Mundim,Fiorita Gonzales Lopes
Grande,Rogério Mendes
Carvalho,Lucas Ribeiro Borges de
Ridolfi,Felipe Moreira
author_sort Engelman,Míriam de Fátima Brasil
title Immunohistochemistry contribution to the diagnosis of prostate cancer
title_short Immunohistochemistry contribution to the diagnosis of prostate cancer
title_full Immunohistochemistry contribution to the diagnosis of prostate cancer
title_fullStr Immunohistochemistry contribution to the diagnosis of prostate cancer
title_full_unstemmed Immunohistochemistry contribution to the diagnosis of prostate cancer
title_sort immunohistochemistry contribution to the diagnosis of prostate cancer
description INTRODUCTION: Efforts for the identification of prostate cancer in the initial clinical and pathological stages led to an increase in the number of biopsies, sometimes making the histological diagnosis of adenocarcinoma difficult. This is due to the presence of minimal carcinoma or atypical glands suspicious for carcinoma, also known as atypical small acinar proliferation (ASAP). In these cases, the use of immunohistochemistry (IHC) has become a common practice in laboratories of pathology. OBJECTIVES: The aims of this study were to assess the incidence of diagnoses of ASAP and minimal adenocarcinoma in two laboratories of pathology and to evaluate the contribution of IHC and repeat biopsy to the diagnosis of prostate cancer. METHODS: We reviewed 641 sets of modified sextant needle biopsies of the prostate performed in two laboratories of pathology between January 2005 and December 2010. IHC using 34βE12 and p63 antibodies was performed on 35 of 73 (11.38%) cases diagnosed as ASAP and on 7 (1.1%) cases diagnosed as minimal adenocarcinoma. RESULTS: The incidence of ASAP diagnosis was 11.38% (n = 73). IHC was performed in 35 of the 73 ASAP cases and provided conclusive results in 31 cases (88.57%), resulting in a final diagnosis of adenocarcinoma in 19 patients (54.28%), benign lesions in 12 patients (34 28%); only 4 (11.42%) were inconclusive. CONCLUSION: The results suggest that IHC should be routinely used in evaluation of borderline biopsies and in ASAP cases. IHC strongly contributes to the diagnosis of prostate cancer.
publisher Sociedade Brasileira de Patologia Clínica
publishDate 2012
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442012000400008
work_keys_str_mv AT engelmanmiriamdefatimabrasil immunohistochemistrycontributiontothediagnosisofprostatecancer
AT mundimfioritagonzaleslopes immunohistochemistrycontributiontothediagnosisofprostatecancer
AT granderogeriomendes immunohistochemistrycontributiontothediagnosisofprostatecancer
AT carvalholucasribeiroborgesde immunohistochemistrycontributiontothediagnosisofprostatecancer
AT ridolfifelipemoreira immunohistochemistrycontributiontothediagnosisofprostatecancer
_version_ 1756427486197972992